Prospective, multicentre trial evaluating FET-PET in Glioblastoma

The FIG trial is investigating how the addition of FET-PET imaging to standard MRI imaging affects radiation target volume delineation and treatment planning for Glioblastoma, as well as determining the accuracy and management impact of FET-PET in distinguishing pseudoprogression from true tumour progression and / or tumour recurrence.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

COGNO, ARTnet, ONJCRI

Participating Centres

Accrual Target

210

Current Accrual

Expected Date of Accrual

31 December 2024

Trial Chairperson

Prof Andrew Scott, Olivia Newton-John Cancer Research Institute (ONJCRI) / The Austin Health, VIC, Australia

A/Prof Eng-Siew Koh, Liverpool Hospital, NSW, Australia

Trial Contact

FIG@trog.com.au

Clinical Trial Registration

Related Post

14 April, 2026

Consumer Engagement Charter cements TROG’s commitment to listen to consumer voices

LATEST NEWS: 14 April 2026 TROG has made a

9 April, 2026

Vale Professor Jim Denham OAM, TROG founder and world-class researcher

9 April 2026 TROG Cancer Research honours the life